ZAI LAB (09688) released its interim results, reporting a net loss of $102 million, with R&D expenses increasing by 14% year-on-year to $127 million.

ZAI LAB (09688) announced its results for the six months ending June 30, 2026, reporting total revenue of $206 million; a net loss of $102 million; and a basic loss per share of $0.09. Research and development expenses increased by $16 million (or 14%) to $127 million, primarily due to an increase in licensing fees under the group's licensing and collaboration agreements. The group believes that the ability to successfully develop candidate products will be a major factor influencing its long-term competitiveness and future growth and development. Developing quality candidate products requires a long-term commitment of substantial resources. The group is dedicated to advancing and expanding its pipeline of potential best-in-class and potential first-in-class products, including through clinical and preclinical trials, as well as business development activities. Therefore, the group expects to continue making significant investments in research and development, including internal discovery activities. In June 2026, the group listed Merrimelin Chloride on the Chinese mainland for the treatment of adult schizophrenia. Merrimelin Chloride is the first new mechanism therapy for schizophrenia in over 70 years, offering a new approach to treating schizophrenia through selective activation of M1 and M4 muscarinic receptors. The group is preparing to seek the inclusion of Merrimelin Chloride in China's national medical insurance catalog in 2027.